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ABSTRACT
Background: Lung cancer in the United States is a substantial cause of mortality.
According to the American College of Radiology’s Lung Cancer Screening Registry,
only 1.9% of eligible patients were screened for lung cancer in 2016. The National
Comprehensive Cancer Network and U.S. Preventative Services Task Force (USPSTF)
guidelines recommend lung cancer screening (LCS) in high-risk patients. The USPSTF
recommends screening current and former smokers aged 55-80 years who have smoked
for 20 or more pack-years, and for former smokers, those that have quit within 15 years.
Purpose: The primary purpose of the study is to determine if a questionnaire screening
tool used in a primary care setting, will increase the number of referrals for lung cancer
screening in patients with tobacco use disorder.
Design Methods: This will be a descriptive, quality improvement practice intervention.
Data will be collected before and after implementation of the project.
Conclusion: Low-dose computed tomography (LDCT) lung cancer screening guidelines
have not been widely implemented into national evidence-based clinical practice as
evidenced by low national lung cancer screening rates. The primary care provider most
often represents the initial point of coordination of preventative care and is a crucial link
between the high-risk lung cancer patients and the LDCT screening center. While this
single site quality improvement project did not show improvement in LDCT screening
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referral rates, it does provide potentially useful data regarding referral rates in Northwest
Georgia.
Keywords: low dose CT, lung cancer screening, lung cancer screening guidelines,
primary care
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INCREASING LUNG CANCER SCREENING REFERRALS IN PATIENTS WITH
TOBACCO USE DISORDER
Introduction
In the United States, lung cancer is the leading cause of cancer-related death
regardless of ethnicity or gender. More than 50% of patients are diagnosed with advanced
or incurable lung cancer at diagnosis. Individuals with Stage III and IV lung cancer have
5-year relative survival rates of 5% and 1%, respectively (American Cancer Society
[ACS], 2021). Tobacco smoking is the number one risk factor for lung cancer and has
been linked to 80% to 90% of all lung cancer cases. Smokers age 55 and older, who have
a minimum of a 20-pack year tobacco smoking history and currently smoke or have quit
within the past 15 years, are at greatest risk for developing lung cancer (United States,
2021).
The American College of Radiology’s Lung Cancer Screening Registry suggested
that in 2016 only 1.9% of eligible patients had been screened. Compliance with lung
cancer screening recommendations is a multifaceted issue and a potential limitation of
lung cancer screening compliance is a lack of knowledge and awareness among primary
care providers (Mukthinuthalapati et al., 2020).
Background
Lung cancer accounts for approximately 25% of cancer mortality in both men and
women and is the leading cause of cancer-related death. (ACS, 2021). The American
Cancer Society's estimates for lung cancer in the United States for 2021 is 235,760 new
cases and approximately 131,880 deaths (2021). Approximately 6.3% of men and women
1

will be diagnosed with lung and bronchus cancer during their lifetime (Howlander, et al.,
2017).
As the data reveals, lung cancer is prevalent in the United States and is a
significant cause of mortality. More people die each year of lung cancer than colon,
breast, and prostate cancers combined (ACS, 2021). Unfortunately, once lung cancer
symptoms arise, it is most likely an advanced stage. The average age of lung cancer
diagnosis is 70 years (ACS, 2021). The lifetime risk that a man will develop lung cancer
is 1 in 15 while, for a woman, the risk is about 1 in 17 (ACS, 2021). The 5-year relative
cancer survival rate for non-small cell lung cancer is about 25% and for small cell lung
cancer it is 7%. Approximately 56% of lung and bronchus cancers are diagnosed after
they have metastasized to distant areas, and the 5-year relative survival rate is only 3% to
7% at that point (ACS, 2021).
The National Comprehensive Cancer Network and U.S. Preventive Services Task
Force (USPSTF) guidelines recommend annual lung cancer screening (LCS) in high-risk
patients. These patients who are considered high risk meet the following guideline
criteria: current and former smokers aged 55-80 years who have smoked for 20 or more
pack-years and currently smoke or have quit within 15 years if a former smoker (Raz et
al., 2016). LCS is a mandated benefit for non-Medicare plans under the Affordable Care
Act and is approved by the Centers for Medicare Services for Medicare beneficiaries
(Raz, et al., 2016). In addition, LCS with low dose computed tomography (LDCT) is
recommended by several other professional societies, including the American Cancer
Society, American Thoracic Society, and the American College of Chest Physicians
2

(Fukunaga, Wiener & Slatore, 2021). Criteria used to determine eligibility are the same
except for the age requirement. Patients with private health insurance are eligible for ages
55-80, whereas, for Medicare, eligibility ages are 55-77. Screening with LDCT disclosed
incidental findings including aortic aneurysms, coronary artery calcifications, and other
lung findings such as emphysema, bronchiectasis, pulmonary fibrosis, and carcinoid
tumors (Agency for Healthcare Research and Quality [AHRQ], 2016).
Problem Statement
Patients and healthcare providers must be informed of the potential benefits of
annual LDCT screening to reach its full potential in reducing lung cancer mortality.
However, two gaps must be filled: the educational gap and the coverage gap. The current
problem is there is no standardized screening tool in place to ensure patients who meet
the screening criteria are getting appropriate referrals (United States Preventive Services
Taskforce [USPSTF], 2021). For many of these high-risk patients, fear is a driving factor
of their willingness to participate in annual screenings, whether the fear is related to the
possibility of receiving a cancer diagnosis or scared to seek medical treatment due to the
presence of certain symptoms, and limit their involvement in lung cancer treatment and
survivorship care (Hamann et al., 2018). This DNP project determined if a questionnaire
increased the number of referrals made for annual lung cancer screening. The PICOT
question for this project is: in patients with current or a history of tobacco use disorder,
will implementation of the USPSTF lung cancer screening increase referrals compared to
no standard screening protocol over 1 month?
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Organizational Description of Project Site
The study took place at an internal medicine office in northwest Georgia, and is
comprised of four physicians, one physician assistant, and one nurse practitioner. Primary
care providers are an integral component in referring patients for necessary health
screenings.
Review of the Literature
The United States Preventive Task Force officially recommended yearly LDCT
screening for patients 55-80 with at least a 20 pack-year history who currently smoke or
have quit smoking in the last 15 years, after the results of the National Lung Screening
Trial (NLST) were released in 2011. This trial demonstrated a 20% reduction in mortality
among patients who received LDCT screening (Okereke, Nishi, Zhou & Goodwin, 2019).
Notably, LDCT is the first cancer screening test found to reduce overall mortality
(USPSTF, 2021). More than 80% of patients with lung cancer are diagnosed at stage III
due to the lack of screening (Okereke et al., 2019).
Lung cancer has a poor overall prognosis, with a survival rate of only 18%, 5
years after diagnosis (Okereke et al., 2019). Most lung cancer diagnoses are made in
advanced stages which is associated with poor prognosis. LDCT screening aims to
combat late detection by finding and diagnosing lung cancer at earlier stages. Lung
cancer detected by LDCT screening will be discovered at an early stage 64% to 85% of
the time (Okereke et al., 2019). Numerous trials and data demonstrate the efficacy of
LDCT lung cancer screening but not using or implementing an effective screening
program for high-risk patients remains the issue (Okereke et al., 2019). After the results
4

of the NLST study were released, lung screening programs were created at numerous
organizations across the country. However, implementation of these programs has not
been widespread. Reports using the Behavioral Risk Factor Surveillance System
(BRFSS) survey estimated that fewer than 5% of eligible patients receive LDCT
screening (Okereke et al., 2019). From this study, Okereke and his colleagues show the
rate of LDCT screening for each month in 2016 and 2017. The rate of screenings rose
throughout 2016 and early 2017 and appeared to plateau by approximately July 2017. In
the multivariate analysis, patients aged 60 to 69 had the highest rates, with those aged 5559 and 75-77 with the lowest rates. Women had 15% lower odds of receiving LDCT
screening (Okereke et al., 2019).
A study from Jemal and Fedawa (2017), claimed there were 8.4 million people
eligible for LDCT screening in 2010. Based off this statistic and considering the United
States Census data, 13.2% of adults aged 55 to 77 years nationwide were eligible for
LDCT screening. Other studies have shown similarly low rates of LDCT screening
(Okereke et al., 2019). These low screening rates are well behind screening rates for
prostate, breast, and colon cancer. It is understandable that it would take time for
providers and the healthcare system to catch up to the recommendation of annual LDCT
screening for the population of interest; however, since May 2017, data suggests there
has been very little increase in screening rates (Jemal & Fedawa, 2017).
The youngest and oldest groups of eligible patients, those aged 55-59 and 75-77,
had the lowest rates of LDCT screening. This could be because patients aged 55 to 59
have not accrued enough pack-years to be eligible for screening. However, given that
5

90% of smokers begin smoking by age 18 or younger, it is more likely that there is a
larger percentage of eligible patients in this range, compared to other ages, who are not
being screened (Okereke et al., 2019). A major reason for this trend may be a lack of
awareness among this population. It is imperative to increase awareness in younger
patients to increase the percentage of patients overall who receive appropriate LDCT
screening. Approximately 12,000 patients between the ages of 55 to 59 die each year
from lung cancer, so increasing screening in this age group is likely to have major impact
in reducing overall lung cancer mortality (Okereke et al., 2019; Jemal & Fedawa, 2017).
The negligible increase in LDCT screening rates after May 2017 suggests that
further measures are required to improve screening rates. Lack of awareness by high-risk
individuals can be improved with advertising by public health to promote the benefits of
screening. It is imperative providers discuss this screening with patients who have a long
smoking history but might not be 55 years of age. Smokers who see a primary care
provider regularly would be more likely to undergo LDCT screening than smokers who
do not frequent a doctor’s office.
Barriers do exist as to why patients are either not being referred for the screening
or decide to not be screened. However, data on these barriers is scant compared to other
cancer screening studies such as mammography. Provider barriers to lung cancer
screening include a lack of awareness regarding guidelines for LCS, lack of time to
counsel patients regarding LCS, or misperceptions regarding the risks and benefits (Raz,
et al., 2016). Primary care providers are the stewards of preventative healthcare,
including lung cancer screening. It is important to estimate how frequently providers are
6

referring patients for LDCT and the providers’ perceptions on guidelines for, relative
benefits of, and barriers to LCS. Possible system barriers include a lack of standardized
methods for identifying patients eligible for LCS, availability to these centers offering
LDCT, and low rates of smokers who have consistent follow-up with primary care
providers.
The National Cancer Institute funded the National Lung Screening Trial to
determine whether screening with LDCT compared with chest radiography would reduce
mortality from lung cancer among high-risk individuals. The participants were
randomized and underwent either LDCT or chest x-ray annually for 3 screens. The NLST
trial is the first randomized screening trial for lung cancer to have shown improvement in
both disease-specific and all-cause mortality (Gutierrez, et al., 2013). The NLST was also
the first trial to provide evidence to support screening for lung cancer with LDCT in
reducing lung cancer deaths. This study randomized 53,454 high-risk individuals aged 55
to 74 years to compare annual screenings with LDCT or standard chest x-rays and
followed them for an average of 6.5 years. Patients were found to be 16 to 20% less
likely to die of lung cancer when screened with LDCT versus standard chest radiographs,
(AHRQ, 2016). This reduction in mortality is equivalent to preventing three lung cancer
deaths per 1,000 people (AHRQ, 2016). Previous studies had shown that screening with
standard chest x-rays does not reduce the mortality rate from lung cancer.
Data from the NLST trial suggests that 10 to 20% of lung carcinomas diagnosed
by LDCT might have never been detected in the patient’s lifetime in the absence of
screening (AHRQ, 2016). Based on this data, an estimated 300 individuals need to be
7

screened to save one life from lung cancer. This estimate compares favorably with
screening mammography, in which some estimates suggest that 465-601 women must be
screened to save one life from breast cancer (Gutierrez et al., 2013). According to Goulart
and Ramsey (2013), 18,000 lung cancer deaths could be prevented annually if LDCT
lung cancer screening were implemented nationally.
Early detection and diagnosis of lung cancer can subsequently reduce the
morbidity and mortality rates associated with lung cancer. However, the risks versus the
benefits on an individual patient basis must be weighed against the unintended harms and
adverse effects of screening for persons exposed to LDCT who did not have lung cancer.
This is why it is important for patients who meet USPSTF eligibility criteria to be
routinely seen by their primary care providers, have discussions regarding the LDCT lung
cancer screening, and when appropriate, be referred annually for screening and compliant
with follow-up protocols.
Evidence-Based Practice: Verification of Chosen Option
Despite widespread recommendations, in the United States healthcare system,
LDCT lung cancer screening remains inadequately implemented. (Lewis et al., 2019).
Most lung cancer diagnoses, approximately 70%, are diagnosed at advanced stages when
curative options are limited, which is why annual screening is so important in high-risk
patients. The current 5-year survival rate is only 18% when lung cancer is detected in an
advanced stage (Lewis et al., 2019). The National Lung Screening Trial found that annual
LDCT decreased the relative lung cancer-specific mortality by 20% and all-cause
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mortality by 6.7% compared with annual chest radiographic screening in high-risk
individuals (Lewis, et al., 2019).
Theoretical Framework/Evidence-Based Practice Model
Nola Pender’s Health Promotion Model (HPM) uses behavioral science to explain
and predict health behaviors (Pender & Pender, 1996). A diagram of the Health
Promotion Model is included in Appendix A (Nola Pender, 2020). This model helps to
identify the influences of biopsychosocial elements that may help engage patients in a
particular health behavior to prevent or reduce the likelihood of negative health outcomes
or improve current health status. The most common health behavior change that utilizes
the HPM is exercise. The health-promoting behavior of interest, in this case, is lung
cancer screening for lung cancer.
The actual and ideal behaviors must be addressed with any health behavior
changes to determine the change that needs to take place. The HPM attempts to close the
gap between the actual and ideal behaviors. The actual behavior for this project includes
current heavy smoking or history of heavy smoking and the ideal behavior being not
smoking. A person will be most likely to make positive health changes when they
perceive the benefits of action or positive outcomes will occur from the health behavior
change. The HPM is about getting to an ideal health status on an individual basis, not
cure, which allows for this model to be applied to a wide variety of health behaviors.
Within the behavioral outcome, a person commits to an achievable planned strategy that
leads to the implementation of the health behavior of interest. When using the HPM, an
individual definition of the current condition is compared to what is envisioned as
9

achievable in terms of improvement. The person also self-determines if the expected
benefit is important and attainable. A person also considers any obstacles in the path of
the behavior change. If any obstacles exist, whether real or perceived, it is more likely the
behavior will not be initiated. Other influences that may determine the likelihood of a
successful behavior change include, but not limited to a person’s lifestyle, beliefs, and
other social determinants of health (Pender & Pender, 1996).
There is a complex relationship between psychological variables such as stigma,
mistrust, fear, and fatalism, and the constructs of the HBM, which allows healthcare
providers to have a complete view of patients needing to undergo lung cancer screening
(Carter-Harris, Davis & Rawl, 2016). Taking these patient beliefs and concerns into
consideration is essential for adapting future interventions with this high-risk population.
Using the Health Promotion Model for lung cancer screening participation
conceptualizes an individual’s willingness to participate in lung cancer screenings and
addresses the psychological reasoning in one’s willingness to participate. The
psychological variables are linked to the traditional HPM constructs that have predicted
participation in screening for other cancers and the shared decision-making process. The
decision to participate is influenced by psychological beliefs, demographic and health
status characteristics, cognitive variables, receiving a healthcare provider
recommendation, social and environmental variables, and personal beliefs regarding lung
cancer (Carter-Harris, et al., 2016).
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Objectives and Expected Outcomes
The objectives of this DNP project were to (1) improve the process of identifying patients
who meet the criteria for the lung cancer screening and (2) ensuring the referral was
made when appropriate. The primary outcome was to measure improvement for LDCT
screening referral of the eligible patients was determined by the responses given from the
questionnaire and the appropriate referral was made.
Project Design
This project was a descriptive, quality improvement practice intervention. Data
was collected before and during the implementation phase of the project to determine the
number of referrals made before and during the implementation of the patient
questionnaire. The Information Technology provided the de-identified data to determine
the number of referrals made per month.
Project Site and Population
The target population is anyone who meets the following USPSTF lung cancer
screening criteria. Adults between 55 and 80 years old who are at high risk for lung
cancer due to being current heavy smokers or have quit within the past 15 years and have
a 20-pack year smoking history, should be screened annually with a low-dose computed
tomography scan. Inclusion criteria are the same guidelines for the lung cancer screening,
which includes adults age 55-80 who currently smoke or have quit smoking in the past 15
years, who have a 20-pack year smoking history. Exclusion criteria includes patients who
do not meet the USPSTF screening criteria.
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Setting Facilitators and Barriers
The Medical Assistants (MA) were crucial to the implementation as they provided
patients the questionnaire when putting them in a room, if the patient met the age criteria
of 55-80. The patient completed the questionnaire while waiting for the provider. The
providers would review the questionnaire and determine if the patient is an appropriate
candidate for the lung cancer screening and made the referral, if indicated.
No obvious barriers existed to the implementation process other than resistance
by providers to order the lung cancer screening when indicated or the screening was
declined by the patient.
Implementation Plan/Procedures
The implementation of the project was vital although it was straightforward. The
MA gave the patient a pen and questionnaire to complete while waiting for the provider if
they were between the ages of 55 and 80. The provider will review the questionnaire and
determine if the patient is a candidate for the screening based on their questionnaire
responses. If the patient met the screening criteria and the patient was willing, a referral
for the LDCT lung cancer screening was sent to the imaging department. The imaging
department would then call the patient to schedule an appointment.
The Information Technology department generated reports with the number of
LDCT referrals that were ordered in a specific time frame. A report was generated for the
2 months before implementation and a second report generated for the 1-month
implementation period to determine if using the questionnaire increased the number of
LDCT referrals. The data from these reports was then given to a statistician to determine
12

if there was a statistically significant relationship of increased LDCT referrals with the
implementation of the questionnaire. The questionnaire is included in Appendix B and
the consent is included in Appendix C.
Measurement Instruments
To measure this DNP Project’s outcome, data was collected by reports generated
from the IT department to determine if using the questionnaire increased the number of
referrals sent for LDCT lung cancer screenings. The number of referrals made in the 2
months before implementation was determined and compared with the number of
referrals made during the implementation period. The questionnaire is in Appendix B and
the informed consent is located in Appendix C.
Data Collection Procedures
If the patient was eligible, the appropriate referral and follow-up was made. The
number of new referrals sent with the questionnaire over one month was compared to the
number of referrals made before implementation of the questionnaire.
This project was designed to aid the adoption of evidence-supported lung cancer
screening into primary care clinical practice by incorporating a questionnaire screening
tool to facilitate referrals. If the patient is eligible, the appropriate referral and follow-up
was made. The number of referrals with the questionnaire over one month was compared
to the number of referrals made before implementation of the questionnaire.
As lung cancer screening is complex, the review of the literature has emphasized
that education of the provider is important in lung cancer screening and was provided
prior to implementation of the questionnaire screening tool. A 10-minute education
13

session with providers was delivered as a refresher as to what the screening guidelines
are. Patients were evaluated as they presented for a regularly scheduled appointment to
represent a primary care office more closely without staff dedicated to a lung cancer
screening program.
Before the MA would bring a patient into an exam room, they would notice the
age of the patient to determine if they needed to give the patient a questionnaire regarding
smoking history to complete while waiting on the provider. The information provided
was reviewed with the patient to calculate the pack-year history and assess the patient’s
risk for lung cancer, undergo smoking cessation counseling, if needed, and refer for
LDCT screening if appropriate.
The data was extracted by the Information Technology department, as they can
determine the number of referrals sent in a specific time frame. No protected health
information (PHI) was collected. As the information is anonymous, there was no way to
determine retrospectively if the patient meets the screening criteria but declined the
screening. Data was then entered into an Excel spreadsheet and sent to a statistician for
analysis. After the one-month implementation period (March 8, 2021 through April 2,
2021), the number of LDCT referrals were measured and compared to the number of
referrals made prior to the questionnaire implementation.
Data Analysis
Descriptive statistics were used to analyze data regarding pre- and postimplementation referrals for LDCT lung cancer screening in patients with tobacco use
disorder. Using the Bayesian Poisson Regression Model, it was difficult to determine the
14

statistical significance as there were very few data points to interpret. Due to low referral
rates pre- and post-implementation, there is no statistical significance that the
questionnaire increased the number of referrals. There is a very low statistical
significance of 12.9% that more than 3 referrals would be sent in 1 month due to the
questionnaire screening tool.
The p-value for this data set is 0.242, meaning that there is a 24.2% chance that in
any given month, there will be 3 or more referrals ordered, and therefore, did not increase
the number of referrals during the implementation period.
Results
Referrals for lung cancer screening were low at this primary practice. In the 2
months pre-implementation, there was 3 referrals made the first month and 1 referral
made the second month. Over the 1-month implementation period, 3 referrals were made.
Factors identified as contributing to patients not being referred for LDCT screening
include the lack of time providers feel they have to discuss this screening with the patient,
patient declination or indecisiveness, pack-year history too short, or the patient had quit
smoking longer than 15 years.
Discussion
The goal of the DNP quality improvement project was to improve lung cancer
screening in patients who meet the USPSTF screening guidelines in a primary care
practice. The process to improve screening included incorporating a questionnaire into
the routine rooming of patients by the medical assistant.
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Utilizing a LDCT screening tool may be challenging during a primary care visit
but it is an important aspect of expanding clinician knowledge and changing clinician
behavior. The short implementation period could have had a role in the lack of statistical
significance (Li, Chung, Wei & Luft, 2018). National LDCT lung cancer screening rates
are low at 1.9% in the general population (Pham, Bhandari, Oechsli, Pinkston, &
Kloecker, 2020). There is currently no data on the estimated or actual numbers of lung
cancer screenings in the Georgia general population for comparison.
Recent debate has questioned if the current USPSTF lung cancer screening
guidelines are too stringent to apply to African American adult smokers, suggesting that
the guidelines may be too conservative for this specific population citing racial
differences in smoking patterns (Aldrich et al., 2019). Suggestions for modification of the
eligibility to 20 pack-years, as well as decreased the minimum age to begin consideration
for LDCT lung cancer screening from the current 55 years to 50 years (Aldrich et al.,
2019).
There may be a larger percentage of people who are patients at this primary care
clinic who do not have any insurance coverage and therefore do not have the coverage for
the LDCT screening as patients with insurance. Numerous patients also do not meet all
the USPSTF guidelines. For example, a patient is 62 years old and has smoked since the
age of 17 but has either stopped smoking numerous times during those years or smoked
less than a pack of cigarettes per day, so he or she would not meet screening guidelines. It
is also possible with the associated stigma surrounding smoking, some patients would
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decline the screening during their appointment. These patients may call the office back
after initially declining to request the referral but there is no way of tracking these add-on
referrals if they took place after the implementation period.
Due to the length of the conversation regarding lung cancer screening, it may be
beneficial for patients to return to their primary care provider for a follow-up
appointment to discuss the LDCT screening as well as allowing for adequate time to
answer questions. Many patients still trust their primary healthcare providers’
recommendations; however, healthcare has evolved and promotes patient-centered care,
which takes into consideration the patient’s values and beliefs regarding their care. The
provider’s role is to educate and guide the patients to health and well-being while
ultimately allowing them to make the final decision. Shared decision making is a crucial
component of the HPM so it is also important that the risks versus benefits and
comorbidities be discussed when determining if the patient should be screened for lung
cancer.
Cost-Benefit Analysis/Budget
This project is extremely affordable for the DNP student and the organization.
The only time involved was for the DNP student creating the questionnaire, the providers
taking the extra 2-20 minutes to review the questionnaire answers, discuss the risks
versus benefits of the LDCT with the patient, order the scan, and the time spent by the
patient completing the scan. It will generally take 30 to 60 minutes to have CT scan
completed with most of the time spent prepping the patient for the scan. No financial
burdens are associated with this project to the office, patient, or DNP student. The early
17

detection of lung cancer, in the long run, will be of financial benefit to the patient as well
as improving quality of life and reducing morbidity and mortality.
Timeline
Project approval took place beginning mid-February with project implementation
starting March 8, 2021 through April 2, 2021. The project timeline is located in Appendix
E. Data collection occurred over those 4 weeks and then a report was generated to
determine the number of LDCT lung cancer screening referrals made during the
implementation period. This data was then given to a statistician for data analysis.
Roughly 1 week was required for this analysis.
Ethical Considerations/Protection of Human Subjects
The Jacksonville State University Institutional Review Board (IRB) approval was
obtained before initiating the DNP project. See Appendix F for the approval letter. Health
Insurance and Portability Act standards were maintained throughout the project,
protecting the patients’ right to privacy. There were no apparent risks to the patients
participating in this project. All spreadsheets and electronic files were password protected
to prevent unauthorized access. Proof of IRB approval is in Appendix F
Conclusion
LDCT lung cancer screening guidelines have not been widely implemented into
national evidence-based clinical practice as evidenced by low national lung cancer
screening rates (ACS, 2021). The primary care provider most often represents the initial
point of coordination of preventative care and is a crucial link between the high-risk lung
cancer patients and the LDCT screening center. Primary care providers are well18

positioned to assist patients with decision-making for lung cancer screening
interventions. However, the primary care setting needs system changes to facilitate this
process. While this single site quality improvement project did not show improvement in
LDCT screening referral rates, it does provide potentially useful data regarding referral
rates in Northwest Georgia.
The United States Preventive Task Force, among other organizations, support the
use of annual LDCT lung cancer screening for high-risk current and former adult
smokers. The decision to be screened should be a shared decision between the patient and
healthcare provider. This DNP project was designed to increase rates of lung cancer
screening referrals and ultimately reduce lung cancer mortality rates. Additional research
needs to be conducted in order to find the best solution to effectively educate patients on
the LDCT screening and healthcare providers on the guidelines in order to appropriately
refer high-risk patients for the screening.
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APPENDIX A

Nola Pender’s Health Promotion Model
Figure 1. Below is Nola Pender’s Health Promotion Model.

(Nola Pender, 2020)
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APPENDIX B

Lung Cancer Screening Questionnaire
1. Do you currently smoke cigarettes?
Yes ☐ (only complete #1) No ☐
How many packs per day (or number of cigarettes per day) do you smoke?
_________packs per day
How many years have you smoked? ________ years
2. Do you have a history of smoking cigarettes?
end)
Did you smoke for 30 years or longer?
end)

Yes ☐
Yes ☐

Have you quit smoking in the last 15 years?

Yes ☐

Thank you for your participation.
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No ☐ (skip to the
No ☐ (skip to the
No ☐

APPENDIX C

Consent form for Questionnaire
Study Title: Increasing Lung Cancer Screening Referrals in Patients with Tobacco Use
Disorder
Purpose
• This study is designed to identify patients who meet screening criteria for lung
cancer based on age and history of smoking cigarettes, and determine if there is
an increase in referrals made for patients who meet the screening criteria.
Participation in the study is anonymous. The primary investigator will be
available to answer any questions you may have.
How long will it take me to do this?
• 5 minutes
Are there any risks of participating in the study?
• No risks to participating in the study.
What are the benefits of participating in the study?
• Creating better coordination to screen for lung cancer in patients who smoke
cigarettes or have smoked for 30 years.
• Early detection of lung cancer
Who can I contact for information about this study?
• Emily Thornberry, NP-C (762)-235-2330
You are free to refuse to participate in this research project or to withdraw your
consent and discontinue participation in the project at any time without penalty.
***My return of this survey implies my consent to participate in this research and I
have been given a second copy of this form to keep for my records*
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APPENDIX D

Agency Letter of Support
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APPENDIX E
Project Timeline
Table 1
Task

Data collection

Data Analysis

March

X

April

May

X

X

X

X

June

July

X

X

Results
presented to

X

local providers
DNP

X

Submission
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